A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Adrian L. Harris(University of Oxford), David Propper(St Bartholomew's Hospital), P. Vasey(Wesley Hospital), A. Turner(Sandwell & West Birmingham Hospitals NHS Trust), Pippa Corrie(University of Cambridge), Frances R. Balkwill(Queen Mary University of London), Andrew Protheroe(University of Oxford), Helena Earl(University of Cambridge), S F Hoare(Queen Mary University of London), Barry W. Hancock(Weston Park Cancer Centre), Chengcheng Han(Asia Pacific Center for Theoretical Physics)
Cited by 48
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k